IFC Holdings Incorporated FL lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 79.4% during the second quarter, Holdings Channel reports. The firm owned 16,950 shares of the biopharmaceutical company’s stock after selling 65,300 shares during the period. IFC Holdings Incorporated FL’s holdings in Halozyme Therapeutics were worth $217,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. IFP Advisors Inc increased its position in shares of Halozyme Therapeutics by 1.6% in the second quarter. IFP Advisors Inc now owns 14,686 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 226 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Halozyme Therapeutics by 2.8% in the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 558 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Halozyme Therapeutics by 1.0% in the first quarter. Janney Montgomery Scott LLC now owns 84,874 shares of the biopharmaceutical company’s stock worth $1,100,000 after buying an additional 877 shares during the last quarter. Creative Planning increased its position in shares of Halozyme Therapeutics by 1.2% in the second quarter. Creative Planning now owns 114,667 shares of the biopharmaceutical company’s stock worth $1,470,000 after buying an additional 1,383 shares during the last quarter. Finally, Sei Investments Co. increased its position in shares of Halozyme Therapeutics by 0.8% in the first quarter. Sei Investments Co. now owns 309,725 shares of the biopharmaceutical company’s stock worth $4,014,000 after buying an additional 2,605 shares during the last quarter. 81.09% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics, Inc. (NASDAQ HALO) opened at 11.90 on Wednesday. The stock has a 50 day moving average price of $12.96 and a 200 day moving average price of $13.14. Halozyme Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $15.20. The firm’s market cap is $1.59 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. During the same quarter in the previous year, the business posted ($0.21) EPS. Halozyme Therapeutics’s revenue was up 1.2% compared to the same quarter last year. Equities research analysts expect that Halozyme Therapeutics, Inc. will post ($0.97) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/ifc-holdings-incorporated-fl-cuts-stake-in-halozyme-therapeutics-inc-halo/1494291.html.

A number of brokerages have issued reports on HALO. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 11th. Piper Jaffray Companies set a $20.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a report on Thursday, August 10th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price target (up from $6.75) on shares of Halozyme Therapeutics in a report on Thursday, August 10th. Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. Halozyme Therapeutics currently has an average rating of “Hold” and an average target price of $14.75.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.